Azopt eye drops Alcon treat glaucoma, open -angle glaucoma (5ml)

Dosage form Bottle x 5ml
Specifications Brinzolamide
Ingredient Glocom glaucoma

Ingredient

Composition information	Content
Brinzolamide	1%

Uses

indicated

Azopt is indicated in case of:

Unit of glaucoma, open -angle glaucoma in the open -angle or contraindication to beta receptor anti -receptor drugs. ANHYDRASE CARBONDRase catalyzes reversible reactions including carbon dioxide hydration reactions and dehydration reactions of carbon dioxide.

The inhibition of the anhydrase carbon dioxide in the eyelids in the eye reduces the secretion of the aquarium, which can be thought to be a way to slow the formation of the next bicarbonate ions with a reduction in sodium and fluid. The result is to reduce the internal pressure (IOP) - a major risk factor in the pathology of the pathology of optic nerve damage and market loss in glaucoma. Brinzolamid inhibits the carbon dioxide II (CA - II), is an isenzyme mainly in the eye, with Ca - II resistance index on In vitro IC50 is 3.2 nm and ki is 0.13 nm.

Pharmacokinetics

absorption

After Azopt eye drops, Brinzolamid is absorbed into the circulatory system and accumulated in red blood cells with a selling time of 111 days. Brinzolamid concentration in red blood cells after a long time of drinking and small eyes reaches the average saturated concentration of 20 µm. N - Desacetyl Brinzolamid metabolites also accumulate in red blood cells after eye drops and medication. However, the level of carbohydrase inhibitor in this saturated level is not enough to have a whole body effect. In addition, the concentrations of Brinzolamid and N - Desacetyl Brinzolamid in plasma after small eyes are close or below quantitative limit.

Distribution

Brinzolamid is moderately cohesive to plasma proteins (about 60%); Therefore, the risk of interacting with other drugs that also connects to plasma proteins is low. Based on studies on white rabbits or colored rabbits show that Brinzolamid is moderately cohesive with melanin. However, Brinzolamid's waste sale time on rabbits is more affected by the cohesion of erythrocytes compared to Melanin cohesion.

On the rabbit, after Azopt's eyes, Brinzolamid is distributed into the eye tissue. After many doses, concentrations in pre -room tissues are higher than that of the room; Meanwhile, after taking multiple doses, the drug accumulates in many tissues of the eye, due to high affinity and closely attached to the II Carbon dicectors II. This leads to the extension of the sale time in the pupils - the eyelashes, veins, retina and lenses similar to the semi -discharged time in the blood (except in the lens that extends the semi -discharged time than in the blood).

After many doses, the accumulation of Brinzolamid in the back tissue such as the retina such as the retina and the vein is the result of blood circulation in these tissues, resulting in extending TMAX time as well as the sale time. In contrast, in aquatic fluid, lens and plasma fluids, due to anhydrase carbon deficiency, and there is no accumulation after taking the drug 2 times/day or 3 times/day, the sale time in these tissues is short.

Metabolism

n - Desethyl Brinzolamid is the main metabolite found in the blood and urine. This metabolite is also known to inhibit anhydrase carbon dioxide. Cytochrome P - 450 CYP3A4 is the main enzyme for this metabolic formation; However, P - 450S also participates in the elimination of Brinzolamid. At a concentration of up to 1000 ng/ml, 100 times higher than the plasma concentration in a stable state, Brinzolamid is not inhibited by P - 450s.

In addition to N - Desethyl Brinzolamid, other metabolites; O - Desmethyl Brinzolamid and N - Desmethoxypropyl Brinzolamid are also found in urine. These metabolites are not specific in humans and are identified in animals in preclinical research after drinking brinzolamid. Do not observe the conversion of isomers R into isomers s.

Elimination

Brinzolamid is excreted mainly through the renal in a constant form (60%) and other 20% are eliminated by metabolism in the liver.

Before taking Azopt eye drops Alcon treat glaucoma, open -angle glaucoma (5ml)

How to use

Shake the vial before use. Only use to eye eye.

To avoid the infection at the head of the medication and the drug chaos, be careful not to put the medication of the drug bottle in contact with the eyelids, the area around the eyes or any object.

Need to press the nose tube or close your eyes after the drug. This will limit the absorption of systemic drugs through the eyes and help reduce the adverse reactions.

After opening the lid, if the attachment is assured, it is necessary to remove it before taking the drug.

Dosage

Adults

The dose of Brinzolamid 1% (Azopt) to treat glaucoma for adult patients with glaucoma or open -angle glaucoma as follows:

Put 1 drop of Azopt phlegm into the disease, 2-3 times daily. If the patient uses more than one eye drops, the medications need to be small at least 10 minutes apart.

Use in children

Not yet established the effectiveness and safety of 1% Brinzolamid in patients under 18 years old and do not recommend use for this object.

Used in people with liver failure and kidney failure

Brinzolamid has not been studied in patients with hepatic impairment and therefore is not recommended for this object,

The drug has not been studied in patients with severe renal impairment (creatinine clearance

Used in the elderly

Not observing the general difference in effectiveness and safety between the elderly and young people. No need to adjust the dose when taking the drug for the elderly.

What to do when overdose?

Need to coordinate symptomatic treatment, supportive treatment.

There may be an electrolyte imbalance, developing metabolic acidosis, and the effects on the nervous system. Must monitor plasma electrolytes (especially potassium levels) and pH level.

What to do when you forget a dose?

Side Effects

When using Azopt medicine, you may experience unwanted effects (ADR).

Common, 1/100 ≤ ADR ≤ 1/10

blurred vision, eye irritation, eye pain, feeling of strange objects in the eyes, congestive eye, taste chaos.

Nasomitis, sore throat, reduced red blood cells, increased chlorine, indifference, depression, depression, reduced libido, nightmares, stress, dementia, dementia, dizziness. Connects, swelling of the eye, gland inflammation, dazzling, fear of light, dry eyes, allergic conjunctivitis, eye dreams, muscular pigments, eye fatigue, discomfort in the eyes, abnormal sensations in the eyes, dry eye syndrome, corneal cysts, conjunctiva conjunctiva, eyelid itching, eye rust, scales, rising eyelashes, increased eye tears. - Laryngeal, throat burning, symptoms of upper respiratory tract, runny nose, sneezing, esophagitis, diarrhea, nausea, vomiting, indigestion, upper abdominal pain, abdominal discomfort, stomach discomfort, flatulence, or diarrhea, digestive disorders, decreased sensation in the mouth, mouth -to -mouth, dry mouth, erythema, red acne, muscle pain, skin pain, skin pain, skin pain, skin pain, skin pain, skin pain, skin pain, tension Pain, abnormalities in the chest, weakness, abnormal feeling, feeling of strange objects in the eyes.

Insomnia, memory impairment, drowsiness, corneal edema, double vision, vision loss, dazzling, reducing sensation in the eyes, edema around the eye sockets, increased intraocular pressure, increased concave rate/plate in the eyes, tinnitus, angina, abnormal heartbeat, sensitive bronchial, upper respiratory tract, stuffy nose, cough, nose, pain, pain, pain, pain, pain eager.

Unknown frequency

rhinitis, hypersensitivity, appetite, tremor, loss of sensation, loss of taste, corneal disorders, eye allergic disorders, eyelash disorders, eyelid disorders, redness around the eyelids, dizziness, heart arrhythmia, fast heart rate, hypertension, reducing heart rate, increased heart rate, asthma, abnormal liver function tests, dermatitis, rash, irregular pain.

Instructions on how to handle ADR

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Azopt drugs contraindicated in the following cases:

Patients with hypersensitivity to Brinzolamid or any ingredients of the drug or sulphonammid.

Patients with severe renal failure.

hypertension metabolic acidosis.

Be cautious when used

The hypersensitivity reactions are common with sulphonamid derivatives that may occur in patients with Azopt eye drops because the drug has systemic absorption. Stop using the drug if there are signs of serious or hypersensitivity side effects.

There have been reports on acid -base balance disorders with oral carbon dioxide inhibitors. Caution used for patients at risk of renal failure due to the risk of metabolic acid infection.

There is no study of the possible role of Brinzolamid on the corneal endothelial function in patients with corneal damage (especially in patients with low levels of endothelial cells).

Carefully monitor patients with corneal damage, such as patients with diabetes or corneal dysplasia.

Azopt eye is small, containing benzalkonium chloride can cause eye irritation and color soft contact lenses. Avoid letting drugs come into contact with soft contact lenses. The patient must remove the contact lenses before using Azopt eye shrine and wait at least 15 minutes before wearing again.

The ability to drive and operate machinery

temporary blurred vision or other vision disorders may affect the ability to drive or operate machinery.

If you are blurred after eye drops, the patient must wait until it is clear and then drive and operate machinery. In addition, there have been reports on neurological disorders when using the drug, which can affect the ability to drive or operate machinery.

Pregnancy

There is no data or data that is limited in the use of Brinzolamid eye drops on pregnant women.

Studies with Brinzolamid on animals shows repeated dose toxicity after using systemic drugs

It is not recommended to use Azopt for pregnant women and women who are likely to not use contraception.

The period of breastfeeding

unknown brinzolamid and the metabolites of the drug excreted through breast milk after small or not; However, the risk for breastfeeding is not excluded. Animal studies after using Brinzolamid oral route are discovered in a minimum of milk. Can not rule out the risk for babies. It is necessary to decide whether whether to stop breastfeeding or stop treating Azopt9 in the mother based on the consideration of the benefits of breastfeeding and the mother's treatment benefits.

Drug interaction

studies on specific interaction between Azopt and other drugs have not been done.

In clinical trials, there is no evidence of adverse interactions when using simultaneously Azopt with similar substances prostaglandin and small eye -catching preparations. The coordination between Azopt and pupils or adrenergic agreeders throughout the therapy for supplementary treatment of glaucoma has not been evaluated.

Azopt is an anhydrase carbonic inhibitor and although used on the spot, the drug is absorbed by the whole body. There have been reports on adid -base balance disorders with oral carbon dioxide inhibitors. It is necessary to consider the ability to interact with drugs in patients using Azopt eye.

may have side effects in addition to the known systemic effects of inhibition of anhydrase carbon dioxide in patients using oral Ca and Azopt inhibitors. It is not recommended to simultaneously use Azopt and oral Ca inhibitors. The isenzyme cytochrom P - 450 plays a role in the transformation of Brinzolamid including CYP3A4 (the main role), CYP2A6, CYP2C8 and CYP2C9. CYP3A4 inhibitors such as ketoconazole, otraconazole, clotrimazol, ritonavir and troleandomycin are expected to inhibit Brinzolamid metabolism through CYP3A4. Therefore, it is necessary to be cautious when used simultaneously with CYP3A4 inhibitors. There is no cumulative brinzolamide accumulation due to the main elimination of the kidneys. Brinzolamid is not an ISOENZYM CYTOCHROM P - 450 inhibitor.

Storage

Store at a temperature not exceeding 30 ° C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.